Clinical Predictors of Aggressive/Disabling Disease: Ulcerative Colitis and Crohn Disease

Gastroenterology Clinics of North America

Volumn 41, Issue 2, 2012, Pages 443-462

  Blonski, Wojciech ^a,b   Buchner, Anna M ^a   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Aggressive disease; Clinical predictors; Crohn disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

COLON RESECTION; COLONOSCOPY; CROHN DISEASE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; MORTALITY; PATIENT COMPLIANCE; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; RECURRENCE RISK; REMISSION; REVIEW; SMOKING; THERAPY RESISTANCE; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; DISABILITY EVALUATION; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84859638626     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.01.008     Document Type: Review

References (71)

1. Farrell R.J., Peppercorn M.A. Ulcerative colitis. Lancet 2002, 359:331-340.
2. Su C., Lichtenstein G. Ulcerative colitis. Sleisenger and Fordtran's gastrointestinal and liver disease 2006, 2499-2549. Saunders Elsevier, Philadelphia. 8th edition. M. Feldman, L. Friedman, L. Brandt (Eds.).
3. Singleton J.W., Law D.H., Kelley M.L., et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979, 77:870-882.
4. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
5. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
6. Farmer R.G., Easley K.A., Rankin G.B. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci 1993, 38:1137-1146.
7. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
8. Hoie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
9. Lundqvist K., Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997, 40:451-456.
10. Kane S.V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577-585.
11. Menees S., Higgins P., Korsnes S., et al. Does colonoscopy cause increased ulcerative colitis symptoms?. Inflamm Bowel Dis 2007, 13:12-18.
12. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107:3-11.
13. Langholz E., Munkholm P., Nielsen O.H., et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991, 26:1247-1256.
14. Hendriksen C., Kreiner S., Binder V. Long term prognosis in ulcerative colitis-based on results from a regional patient group from the county of Copenhagen. Gut 1985, 26:158-163.
15. Stonnington C.M., Phillips S.F., Zinsmeister A.R., et al. Prognosis of chronic ulcerative colitis in a community. Gut 1987, 28:1261-1266.
16. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523. [quiz: 24].
17. Langholz E., Munkholm P., Davidsen M., et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444-1451.
18. Travis S.P., Farrant J.M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38:905-910.
19. Leijonmarck C.E., Persson P.G., Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut 1990, 31:329-333.
20. Langholz E., Munkholm P., Davidsen M., et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996, 31:260-266.
21. Hoie O., Wolters F.L., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007, 132:507-515.
22. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440.
23. Ananthakrishnan A.N., Issa M., Beaulieu D.B., et al. History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflamm Bowel Dis 2009, 15:176-181.
24. Jess T., Gamborg M., Munkholm P., et al. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007, 102:609-617.
25. Sinclair T.S., Brunt P.W., Mowat N.A. Nonspecific proctocolitis in northeastern Scotland: a community study. Gastroenterology 1983, 85:1-11.
26. Ayres R.C., Gillen C.D., Walmsley R.S., et al. Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996, 8:555-558.
27. Powell-Tuck J., Ritchie J.K., Lennard-Jones J.E. The prognosis of idiopathic proctitis. Scand J Gastroenterol 1977, 12:727-732.
28. Andres P.G., Friedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999, 28:255-281. vii.
29. Moayyeri A., Daryani N.E., Bahrami H., et al. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol 2005, 20:366-370.
30. Papatheodoridis G.V., Hamilton M., Mistry P.K., et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998, 43:639-644.
31. Gurbuz A.K., Giardiello F.M., Bayless T.M. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995, 38:37-41.
32. Broome U., Lofberg R., Veress B., et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404-1408.
33. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
34. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
35. Elloumi H., Ben Abdelaziz A., Derbel F., et al. Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis. Acta Gastroenterol Belg 2005, 68:226-229.
36. Cassinotti A., Actis G.C., Duca P., et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009, 104:2760-2767.
37. Evans J.M., McMahon A.D., Murray F.E., et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619-622.
38. Felder J.B., Korelitz B.I., Rajapakse R., et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949-1954.
39. Meyer A.M., Ramzan N.N., Heigh R.I., et al. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006, 51:168-172.
40. Takeuchi K., Smale S., Premchand P., et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196-202.
41. Sandborn W.J., Stenson W.F., Brynskov J., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4:203-211.
42. Bonner G.F., Fakhri A., Vennamaneni S.R. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751-757.
43. Kane S., Huo D., Aikens J., et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003, 114:39-43.
44. Mahid S.S., Minor K.S., Soto R.E., et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006, 81:1462-1471.
45. Rudra T., Motley R., Rhodes J. Does smoking improve colitis?. Scand J Gastroenterol Suppl 1989, 170:61-63. [discussion: 6-8].
46. de Castella H. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) 1982, 284:1706.
47. Abraham N., Selby W., Lazarus R., et al. Is smoking an indirect risk factor for the development of ulcerative colitis?. An age- and sex-matched case-control study. J Gastroenterol Hepatol 2003, 18:139-146.
48. Boyko E.J., Perera D.R., Koepsell T.D., et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988, 23:1147-1152.
49. Beaugerie L., Massot N., Carbonnel F., et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001, 96:2113-2116.
50. Nishio Y., Ando T., Maeda O., et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006, 55:1768-1773.
51. Fujiya M., Saitoh Y., Nomura M., et al. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointest Endosc 2002, 56:535-542.
52. Watanabe C., Sumioka M., Hiramoto T., et al. Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis. Inflamm Bowel Dis 2009, 15:1663-1669.
53. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
54. Schirbel A., Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 2010, 11:266-276.
55. Gasche C., Scholmerich J., Brynskov J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6:8-15.
56. Louis E., Collard A., Oger A.F., et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
57. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
58. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
59. Munkholm P., Langholz E., Davidsen M., et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30:699-706.
60. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5:1430-1438.
61. Veloso F.T., Ferreira J.T., Barros L., et al. Clinical outcome of Crohn's disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis 2001, 7:306-313.
62. Greenstein A.J., Lachman P., Sachar D.B., et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988, 29:588-592.
63. Bernell O., Lapidus A., Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000, 231:38-45.
64. Ramadas A.V., Gunesh S., Thomas G.A., et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59:1200-1206.
65. Szamosi T., Banai J., Lakatos L., et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2010, 22:872-879.
66. Reese G.E., Nanidis T., Borysiewicz C., et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008, 23:1213-1221.
67. Duricova D., Pedersen N., Elkjaer M., et al. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010, 16:347-353.
68. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
69. Lakatos P.L., Czegledi Z., Szamosi T., et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009, 15:3504-3510.
70. Cosnes J., Beaugerie L., Carbonnel F., et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001, 120:1093-1099.
71. Seksik P., Nion-Larmurier I., Sokol H., et al. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009, 15:734-741.